AVTX Insider Trading Activity and SEC Form 4 Filings
AVTX insider trading summary
Over the past 12 months, insiders at Avalo Therapeutics, Inc. (AVTX) reported 37 sales worth $8.1M by 6 insiders and no open-market purchases on SEC Form 4. Net insider selling was $8.1M.
Latest AVTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 16, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | $202K (12,394 @ $16.33) |
| Sep 10, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | $179K (10,185 @ $17.62) |
| Aug 28, 2026 | Mittie Doyle | Chief Medical Officer | Sell | $14K (679 @ $20.00) |
| Aug 18, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | $622K (31,031 @ $20.05) |
| Aug 17, 2026 | Mittie Doyle | Chief Medical Officer | Sell | $20K (1,000 @ $20.00) |
| Aug 17, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | $753K (37,945 @ $19.85) |
| Aug 17, 2026 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | $75K (3,749 @ $19.94) |
| Aug 11, 2026 | Jennifer Riley | Chief Strategy Officer | Sell | $52K (2,655 @ $19.59) |
| Aug 10, 2026 | Mittie Doyle | Chief Medical Officer | Sell | $14K (679 @ $20.00) |
| May 15, 2026 | Mittie Doyle | Chief Medical Officer | Sell | $56K (3,000 @ $18.76) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.